MeiraGTx (NASDAQ:MGTX) PT Lowered to $22.00

MeiraGTx (NASDAQ:MGTX – Get Rating) had its price objective reduced by Royal Bank of Canada from $27.00 to $22.00 in a research report report published on Wednesday morning, The Fly reports. They currently have an outperform rating on the stock.

MeiraGTx Stock Down 8.3 %

MGTX stock opened at $5.41 on Wednesday. The company has a quick ratio of 2.14, a current ratio of 1.88 and a debt-to-equity ratio of 0.75. The firm has a market capitalization of $263.28 million, a PE ratio of -1.89 and a beta of 1.44. MeiraGTx has a twelve month low of $5.34 and a twelve month high of $15.16. The stock has a 50-day simple moving average of $7.33 and a two-hundred day simple moving average of $7.29.

Institutional Trading of MeiraGTx

A number of large investors have recently modified their holdings of the business. Alliancebernstein L.P. boosted its position in shares of MeiraGTx by 6.8% during the 4th quarter. Alliancebernstein L.P. now owns 36,200 shares of the company’s stock valued at $236,000 after acquiring an additional 2,300 shares during the last quarter. Silverarc Capital Management LLC boosted its position in shares of MeiraGTx by 2.4% during the 4th quarter. Silverarc Capital Management LLC now owns 56,672 shares of the company’s stock valued at $370,000 after acquiring an additional 1,330 shares during the last quarter. Morgan Stanley boosted its position in shares of MeiraGTx by 52.4% during the 4th quarter. Morgan Stanley now owns 90,479 shares of the company’s stock valued at $590,000 after acquiring an additional 31,127 shares during the last quarter. Algert Global LLC bought a new stake in shares of MeiraGTx during the 4th quarter valued at about $166,000. Finally, Atom Investors LP boosted its position in shares of MeiraGTx by 27.7% during the 4th quarter. Atom Investors LP now owns 26,751 shares of the company’s stock valued at $174,000 after acquiring an additional 5,804 shares during the last quarter. Institutional investors own 70.10% of the company’s stock.

MeiraGTx Company Profile

(Get Rating)

MeiraGTx Holdings Plc engages in the development of novel gene therapy treatments. It focuses on inherited retinal diseases, neurodegenerative diseases, and severe forms of xerostomia. It operates through the following geographical segments: United States, Ireland, Netherlands, and United Kingdom. Its pipeline includes AAV CNGB3, AAV-CNGA3, AAV-RPE65, AAV-RPGR, AAV-AQP1 and AAV-UPF1.